Our
News
Check back on a regualr basis
for futher updates.
VasoDynamics files global patent (PCT) for NG11-2 platform formulation and production
VasoDynamics files global patent (PCT) for NG11-2 platform formulation and production Platform Intellectual Property protection extended to 2042 5th March 2022 - VasoDynamics Ltd, the pharmaceutical
VasoDynamics strengthens Board and management team with key appointments
VasoDynamics strengthens Board and management team with key appointments Building a strong team of industry experts as clinical programmes progress • Paul Stainer, Director and Chief
VasoDynamics attracts £1.9m from new investors
VasoDynamics attracts £1.9m from new investors Additional funding to support the clinical development of NG11-2 30th November 2021 - VasoDynamics Ltd, the pharmaceutical company developing patient-friendly
VasoDynamics completes MHRA advisory meeting for NG11-2 clinical development
VasoDynamics completes MHRA advisory meeting for NG11-2 clinical development Phase Ib design and study objectives agreed 21st September 2021 - VasoDynamics Ltd, the pharmaceutical company developing
VasoDynamics appoints Gill Jennings & Every LLP of London.
VasoDynamics appoints Gill Jennings & Every LLP of London. By Gary Bower I 29th June 2021 Gill Jennings & Every (GJE) is a leading intellectual property
VasoDynamics becomes a member of UK BioIndustry Association (BIA) and attends the BIA Start-up Festival virtual event on 19th May 2021.
VasoDynamics becomes a member of UK BioIndustry Association (BIA) and attends the BIA Start-up Festival virtual event on 19th May 2021. Amir khan May 20, 2021 BioIndustry